Recurrent Mantle Cell Lymphoma Recruiting Phase 1 / 2 Trials for Nivolumab (DB09035)

Also known as: Mantle Cell Lymphoma Recurrent

IndicationStatusPhase
DBCOND0028615 (Recurrent Mantle Cell Lymphoma)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03015896Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin LymphomaTreatment